Awarded Alzheimer’s Association Grant to Target Microglia in Alzheimer’s Disease

Taipei City, Taiwan, August 26, 2020 – Elixiron Immunotherapeutics Inc. today announced that it has been awarded a $1,000,000 grant from the Alzheimer's Association under the 2020 Part the Cloud program to support a US FDA-approved first-in-human phase 1 clinical trial of its lead drug candidate, EI1071, an orally available, highly potent Colony-Stimulating Factor 1 Receptor (CSF1R) inhibitor. Read the press release here.